Abstract
Upon viral exposure, antibodies serve as a first line of defense and can act by preventing infection or reducing the viral burden. The ability of antibodies to confer protection against HIV has been demonstrated by several studies using the passive transfer of neutralizing antibodies in the non-human primate challenge model. Therefore, efforts have been made to induce a similarly protective humoral immune response by vaccination with antigens derived from HIV. Thus far, the results have been disappointing. Humoral immune responses elicited via vaccination display activities that are generally much less potent and broad as compared to those induced during natural infection. However, recently there have been increased efforts to systematically identify and compare the epitopes potentially critical to the generation of protective antibody responses in the hope that this will lead to improved strategies and superior immunogen design. As a critical part of this process, novel methods to monitor protective antibody responses will also need to be vigorously explored and improved, then validated in both preclinical and clinical settings.
Keywords: HIV, antibodies, neutralization, epitopes
Current HIV Research
Title: Broadening Our View of Protective Antibody Responses Against HIV
Volume: 5 Issue: 6
Author(s): Brian Burke and Susan W. Barnett
Affiliation:
Keywords: HIV, antibodies, neutralization, epitopes
Abstract: Upon viral exposure, antibodies serve as a first line of defense and can act by preventing infection or reducing the viral burden. The ability of antibodies to confer protection against HIV has been demonstrated by several studies using the passive transfer of neutralizing antibodies in the non-human primate challenge model. Therefore, efforts have been made to induce a similarly protective humoral immune response by vaccination with antigens derived from HIV. Thus far, the results have been disappointing. Humoral immune responses elicited via vaccination display activities that are generally much less potent and broad as compared to those induced during natural infection. However, recently there have been increased efforts to systematically identify and compare the epitopes potentially critical to the generation of protective antibody responses in the hope that this will lead to improved strategies and superior immunogen design. As a critical part of this process, novel methods to monitor protective antibody responses will also need to be vigorously explored and improved, then validated in both preclinical and clinical settings.
Export Options
About this article
Cite this article as:
Burke Brian and Barnett W. Susan, Broadening Our View of Protective Antibody Responses Against HIV, Current HIV Research 2007; 5 (6) . https://dx.doi.org/10.2174/157016207782418533
DOI https://dx.doi.org/10.2174/157016207782418533 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Letters in Drug Design & Discovery Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation
Current Medical Imaging The Bioactive Acidic Serine- and Aspartate-Rich Motif Peptide
Current Protein & Peptide Science Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Anti-Insulin Receptor Antibodies in the Pathology and Therapy of Diabetes Mellitus
Current Diabetes Reviews Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design Cancer Electrogene Therapy with Interleukin-12
Current Gene Therapy Spatial Proteomics Sheds Light on the Biology of Nucleolar Chaperones
Current Proteomics Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research “Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin
Current Cancer Drug Targets